Veliković V, Metlas R, Danilo V, Cavor L, Pejinović N, Dujuć A, Zakhariev S, Guarnaccia C, Pongor S
Laboratory for Multidisciplinary Research 180/2, Institute of Nuclear Sciences, VINCA, Beograd, Yugoslavia.
Biochem Biophys Res Commun. 1993 Nov 15;196(3):1019-24. doi: 10.1006/bbrc.1993.2353.
It was recently shown that peptide NTM (RSANFTDNAKTIIVQLNESV), corresponding to residues 280-299 in the second conserved domain of HIV-1 envelope glycoprotein gp120, has spectral and sequence similarity with human vasoactive intestinal peptide, VIP (Veljkovic et al., Biochem. Biophys. Res. Commun., 189, 705-710, 1992). We found that natural autoantibodies cross-reactive with this peptide can be detected in sera from HIV-negative asthma patients and healthy blood donors. The level of these antibodies is significantly higher in asthma patients than in healthy individuals, suggesting that these antibodies can in fact be at least partly identical to natural anti-VIP antibodies previously described (Paul et al., Biochem. Biophys. Res. Commun., 130, 479-483, 1985; Paul et al., Science, 244, 158-1162, 1989). Possible origin and role of these antibodies in AIDS pathogenesis and therapy are discussed.
最近研究表明,与HIV-1包膜糖蛋白gp120第二个保守结构域中280 - 299位残基相对应的肽NTM(RSANFTDNAKTIIVQLNESV)与人类血管活性肠肽VIP具有光谱和序列相似性(Veljkovic等人,《生物化学与生物物理研究通讯》,第189卷,第705 - 710页,1992年)。我们发现,在HIV阴性哮喘患者和健康献血者的血清中可检测到与该肽发生交叉反应的天然自身抗体。哮喘患者体内这些抗体的水平显著高于健康个体,这表明这些抗体实际上可能至少部分与先前描述的天然抗VIP抗体相同(Paul等人,《生物化学与生物物理研究通讯》,第130卷,第479 - 483页,1985年;Paul等人,《科学》,第244卷,第158 - 1162页,1989年)。本文讨论了这些抗体在艾滋病发病机制和治疗中的可能来源及作用。